Intravitreal Triamcinolone Acetonide Use in Diabetic Macular Edema: Illustrative Cases
- PMID: 20337278
- DOI: 10.3928/15428877-20100215-95
Intravitreal Triamcinolone Acetonide Use in Diabetic Macular Edema: Illustrative Cases
Abstract
The role of intravitreal triamcinolone acetonide (IVTA) for patients with diabetic macular edema is controversial. Three diabetic macular edema case studies are presented to illustrate short-term outcomes. The main outcome measures included visual acuity (VA), optical coherence tomography (OCT), macular thickening (in microns), and improvement in visual acuity. IVTA appears to have short-term efficacy in selected patients with diabetic macular edema, and it is a reasonable treatment option for patients with very poor presenting VA. A controlled prospective study to evaluate the emerging role of IVTA in combination with other treatment options for diabetic macular edema, especially among patients with poor VA at presentation, is underway through the Diabetic Retinopathy Clinical Research network.
Copyright 2010, SLACK Incorporated.
Similar articles
-
The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.Semin Ophthalmol. 2015 Jul;30(4):276-80. doi: 10.3109/08820538.2013.847110. Epub 2013 Nov 19. Semin Ophthalmol. 2015. PMID: 24251435
-
Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.Retina. 2015 Feb;35(2):272-9. doi: 10.1097/IAE.0000000000000300. Retina. 2015. PMID: 25105313
-
Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema.Retina. 2011 Apr;31(4):748-54. doi: 10.1097/IAE.0b013e3181f04991. Retina. 2011. PMID: 21836404
-
Efficacy and safety of triamcinolone acetonide injection combined with laser photocoagulation in the treatment of diabetic macular edema: a systematic review and meta-analysis.Ann Palliat Med. 2021 Dec;10(12):12467-12477. doi: 10.21037/apm-21-3274. Ann Palliat Med. 2021. PMID: 35016410
-
Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.Curr Drug Targets. 2011 Feb;12(2):149-72. doi: 10.2174/138945011794182746. Curr Drug Targets. 2011. PMID: 20887246 Review.
Cited by
-
Small RNA Sequencing Reveals a Distinct MicroRNA Signature between Glucocorticoid Responder and Glucocorticoid Non-Responder Primary Human Trabecular Meshwork Cells after Dexamethasone Treatment.Genes (Basel). 2023 Oct 27;14(11):2012. doi: 10.3390/genes14112012. Genes (Basel). 2023. PMID: 38002955 Free PMC article.
-
Glucocorticoid Receptor Transactivation Is Required for Glucocorticoid-Induced Ocular Hypertension and Glaucoma.Invest Ophthalmol Vis Sci. 2019 May 1;60(6):1967-1978. doi: 10.1167/iovs.18-26383. Invest Ophthalmol Vis Sci. 2019. PMID: 31050723 Free PMC article.
-
Intravitreal Corticosteroids in the Management of Diabetic Macular Edema.Curr Ophthalmol Rep. 2013 Sep;1(3):10.1007/s40135-013-0015-3. doi: 10.1007/s40135-013-0015-3. Curr Ophthalmol Rep. 2013. PMID: 24224143 Free PMC article.
-
Update on corticosteroids for diabetic macular edema.Clin Ophthalmol. 2016 Sep 8;10:1723-30. doi: 10.2147/OPTH.S115546. eCollection 2016. Clin Ophthalmol. 2016. PMID: 27660409 Free PMC article. Review.
-
Centrifuged-Concentrated Intravitreal Slurry Triamcinolone Acetonide: An Inexpensive, Easy, and Viable Alternative to Long-Term Steroid Delivery.J Vitreoretin Dis. 2020 Sep 2;5(1):15-31. doi: 10.1177/2474126420943417. eCollection 2021 Jan-Feb. J Vitreoretin Dis. 2020. PMID: 37009586 Free PMC article.